ZA202005459B - Methods of use and pharmaceutical compositions of a selective syk inhibitor - Google Patents
Methods of use and pharmaceutical compositions of a selective syk inhibitorInfo
- Publication number
- ZA202005459B ZA202005459B ZA2020/05459A ZA202005459A ZA202005459B ZA 202005459 B ZA202005459 B ZA 202005459B ZA 2020/05459 A ZA2020/05459 A ZA 2020/05459A ZA 202005459 A ZA202005459 A ZA 202005459A ZA 202005459 B ZA202005459 B ZA 202005459B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- pharmaceutical compositions
- syk inhibitor
- selective
- selective syk
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641094P | 2018-03-09 | 2018-03-09 | |
| US201862663999P | 2018-04-27 | 2018-04-27 | |
| PCT/US2019/021402 WO2019173744A1 (en) | 2018-03-09 | 2019-03-08 | Methods of use and pharmaceutical compositions of a selective syk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202005459B true ZA202005459B (en) | 2023-02-22 |
Family
ID=65818744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/05459A ZA202005459B (en) | 2018-03-09 | 2020-09-01 | Methods of use and pharmaceutical compositions of a selective syk inhibitor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210052582A1 (https=) |
| EP (1) | EP3761986A1 (https=) |
| JP (1) | JP7417531B2 (https=) |
| KR (1) | KR20210018193A (https=) |
| CN (2) | CN112243375A (https=) |
| AU (1) | AU2019230220B2 (https=) |
| BR (1) | BR112020018377A2 (https=) |
| CA (1) | CA3093371A1 (https=) |
| IL (1) | IL277093A (https=) |
| MX (1) | MX2020009396A (https=) |
| PH (1) | PH12020551418A1 (https=) |
| SG (1) | SG11202008765UA (https=) |
| TW (1) | TWI805705B (https=) |
| WO (1) | WO2019173744A1 (https=) |
| ZA (1) | ZA202005459B (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007056457A2 (en) * | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| KR101454674B1 (ko) | 2006-03-17 | 2014-10-27 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물 |
| MX2010011463A (es) * | 2008-04-16 | 2011-06-03 | Portola Pharm Inc | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. |
| SG2014015085A (en) * | 2008-04-16 | 2014-06-27 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
| KR20140103168A (ko) * | 2011-12-16 | 2014-08-25 | 알러간, 인코포레이티드 | 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물 |
| AR090650A1 (es) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| EP2897950A1 (en) * | 2012-09-18 | 2015-07-29 | Ziarco Pharma Ltd | 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors |
-
2019
- 2019-03-08 CN CN201980017916.9A patent/CN112243375A/zh active Pending
- 2019-03-08 TW TW108107933A patent/TWI805705B/zh not_active IP Right Cessation
- 2019-03-08 AU AU2019230220A patent/AU2019230220B2/en active Active
- 2019-03-08 JP JP2020547139A patent/JP7417531B2/ja active Active
- 2019-03-08 EP EP19712475.3A patent/EP3761986A1/en active Pending
- 2019-03-08 KR KR1020207028762A patent/KR20210018193A/ko active Pending
- 2019-03-08 CA CA3093371A patent/CA3093371A1/en active Pending
- 2019-03-08 US US16/979,075 patent/US20210052582A1/en not_active Abandoned
- 2019-03-08 BR BR112020018377-6A patent/BR112020018377A2/pt not_active Application Discontinuation
- 2019-03-08 SG SG11202008765UA patent/SG11202008765UA/en unknown
- 2019-03-08 WO PCT/US2019/021402 patent/WO2019173744A1/en not_active Ceased
- 2019-03-08 CN CN202411182880.9A patent/CN119235862A/zh active Pending
- 2019-03-08 MX MX2020009396A patent/MX2020009396A/es unknown
-
2020
- 2020-09-01 IL IL277093A patent/IL277093A/en unknown
- 2020-09-01 ZA ZA2020/05459A patent/ZA202005459B/en unknown
- 2020-09-09 PH PH12020551418A patent/PH12020551418A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202008765UA (en) | 2020-10-29 |
| US20210052582A1 (en) | 2021-02-25 |
| TWI805705B (zh) | 2023-06-21 |
| AU2019230220A1 (en) | 2020-10-08 |
| KR20210018193A (ko) | 2021-02-17 |
| PH12020551418A1 (en) | 2021-09-01 |
| MX2020009396A (es) | 2021-01-15 |
| IL277093A (en) | 2020-10-29 |
| BR112020018377A2 (pt) | 2021-03-09 |
| AU2019230220B2 (en) | 2025-01-30 |
| CN119235862A (zh) | 2025-01-03 |
| JP2021517139A (ja) | 2021-07-15 |
| CA3093371A1 (en) | 2019-09-12 |
| EP3761986A1 (en) | 2021-01-13 |
| JP7417531B2 (ja) | 2024-01-18 |
| WO2019173744A1 (en) | 2019-09-12 |
| CN112243375A (zh) | 2021-01-19 |
| TW202002980A (zh) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276095B1 (en) | gcn2 inhibitors and their uses | |
| IL267291A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL274504A (en) | 2ACSS inhibitors and methods of their use | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| LT3700902T (lt) | Trpc6 inhibitoriai | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| EP3336090A4 (en) | INHIBITOR OF IRAQ4 AND ITS USE | |
| HUE059778T2 (hu) | URAT1-inhibitor és alkalmazása | |
| IL280051A (en) | EP4 inhibitors and their synthesis | |
| IL276135A (en) | Preparations and methods of use | |
| PL3621694T3 (pl) | Inhibitory lrrc33 i ich zastosowanie | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| EP3672922A4 (en) | WALL DIMENSIONS AND METHOD OF USE | |
| ZA202103580B (en) | Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same | |
| IL281342A (en) | Preparations include a CRAC inhibitor and a corticosteroid and methods of using them | |
| GB2589398B (en) | Compounds and methods of use | |
| SG11202103965TA (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| EP3924335A4 (en) | ANTI-FIBROTIC NEU3 INHIBITOR COMPOUNDS AND METHODS OF USE | |
| ZA202005459B (en) | Methods of use and pharmaceutical compositions of a selective syk inhibitor | |
| ZA202104656B (en) | Deuterated forms and derivatives of volinanserin | |
| HK40041793A (en) | Methods of use and pharmaceutical compositions of a selective syk inhibitor | |
| GB201908573D0 (en) | Compounds and methods of use | |
| AU2015902765A0 (en) | Novel aminopeptidase inhibitors and methods of use |